gurufocus.com · 30 jun

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS

[url="]Interactive Brokers[/url] (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea

zacks.com · 29 jun

New Strong Sell Stocks for June 29th

ATS, BXBLY and SKY have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2026.

zacks.com · 22 jun

Implied Volatility Surging for ATS Corporation Stock Options

Investors need to pay close attention to ATS stock based on the movements in the options market lately.

globenewswire.com · 18 jun

Fusemachines Expands Access to Agentic AI for Talent Acquisition Through Broad ATS Connectivity

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. (NASDAQ: FUSE), a leading provider of enterprise AI products and services, today announced expanded enterprise access to its Agentic AI for Talent Acquisition platform through new connectivity with more than 30 enterprise applicant tracking systems (ATS), enabling Fusemachines Agents to work directly within the systems organizations already use to manage talent and hiring. This expanded connectivity represents the first in a broader series of planned platform enhancements designed to bring AI-powered recruiting capabilities closer to the workflows, data, and systems recruiters rely on every day.

globenewswire.com · 18 jun

New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF

Not intended for UK and US audiences  Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses. Based on the modeling, nerandomilast consistently increased median survival in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).1,2 Modeling predicts meaningful extensions in survival with nerandomilast, including a multi-year increase in median survival when used as monotherapy, and additional gains when added to standard treatment.1,2 Ingelheim, Germany - Long-term survival modeling of Boehringer Ingelheim's oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis (IPF) and up to 3.3 years in adults with progressive pulmonary fibrosis (PPF), compared with no therapy.1,2 These findings are based on data from the Phase III FIBRONEER™ trials and were recently presented at the ATS and EULAR 2026 international congresses.

zacks.com · 15 jun

New Strong Sell Stocks for June 15th

ATS, BFC and CMC have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2026.

businesswire.com · 8 jun

ATS to Participate in the Stifel Summer Solstice Conference

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Anne Cybulski, Interim Chief Financial Officer, will participate in the Stifel Summer Solstice Conference in Muskoka, ON on June 16, 2026. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Stifel representative or docampo@atsautomation.com. About ATS Corporation ATS Corporation is an industry-leading automation s.

gurufocus.com · 5 jun

Securitize and Cantor Equity Partners II Announce SEC Declaration of Effectiveness of Registration Statement on Form S-4

Securitize and Cantor Equity Partners II Announce SEC Declaration of Effectiveness of Registration Statement on Form S-4 PR New